Loading...
XSHE000623
Market cap2.67bUSD
Jan 17, Last price  
16.44CNY
1D
0.00%
1Q
-2.50%
Jan 2017
-31.38%
Name

Jilin Aodong Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:000623 chart
P/E
13.47
P/S
5.70
EPS
1.22
Div Yield, %
1.72%
Shrs. gr., 5y
0.46%
Rev. gr., 5y
0.74%
Revenues
3.45b
+20.25%
820,775,199767,321,745770,228,862845,146,602927,821,7911,025,515,4981,113,327,7671,145,230,6671,445,463,1701,956,861,1712,240,099,3442,334,760,8372,736,697,0772,976,771,6443,324,078,2653,088,379,5912,251,650,9502,303,763,7632,868,211,4643,449,123,301
Net income
1.46b
-18.02%
116,848,518110,522,797387,923,0301,992,259,763861,607,7961,366,488,9811,237,656,4651,982,049,203646,417,2061,058,789,4021,410,692,5452,593,589,3161,666,491,3611,863,471,361935,187,8931,403,640,3131,708,876,0521,780,500,3671,780,801,3451,459,879,678
CFO
68m
-83.94%
218,534,941136,255,140187,992,627384,693,029235,027,833213,027,240174,221,772108,303,405272,401,616201,217,819288,827,750388,032,364333,812,958256,485,969347,635,221379,456,901390,408,759324,846,060423,856,81568,060,613
Dividend
Jul 09, 20240.6 CNY/sh

Profile

Jilin Aodong Pharmaceutical Group Co., Ltd. produces and sells pharmaceutical products in China. The company offers various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It also engages in the highway construction and toll collection businesses; animal husbandry activities; manufacture of specialty chemicals; production and supply of heat and water; wholesale, retail, and distribution of medicines; packaging design and printing activities; production and sale of medicinal packaging materials; and information consulting and advertising design activities. The company was founded in 1957 and is headquartered in Dunhua, China.
URL
http://www.jlaod.com/
IPO date
Oct 28, 1996
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,449,123
20.25%
2,868,211
24.50%
Cost of revenue
3,057,022
2,473,643
Unusual Expense (Income)
NOPBT
392,101
394,568
NOPBT Margin
11.37%
13.76%
Operating Taxes
55,833
Tax Rate
14.24%
NOPAT
336,268
394,568
Net income
1,459,880
-18.02%
1,780,801
0.02%
Dividends
(338,084)
(341,091)
Dividend yield
1.88%
1.75%
Proceeds from repurchase of equity
(149,999)
BB yield
0.83%
Debt
Debt current
696,191
669,503
Long-term debt
42,987
2,338,456
Deferred revenue
247,375
281,603
Other long-term liabilities
2
Net debt
(23,983,645)
(20,320,972)
Cash flow
Cash from operating activities
68,061
423,857
CAPEX
(419,521)
Cash from investing activities
763,616
Cash from financing activities
(549,207)
FCF
1,497,741
311,878
Balance
Cash
3,378,275
3,078,245
Long term investments
21,344,549
20,250,686
Excess cash
24,550,368
23,185,521
Stockholders' equity
27,992,956
26,768,611
Invested Capital
3,914,304
6,371,094
ROIC
6.54%
6.05%
ROCE
1.38%
1.33%
EV
Common stock shares outstanding
1,189,602
1,300,746
Price
15.14
1.00%
14.99
-18.84%
Market cap
18,010,576
-7.63%
19,498,185
-16.12%
EV
(5,685,061)
(519,239)
EBITDA
631,762
620,195
EV/EBITDA
Interest
144,348
142,993
Interest/NOPBT
36.81%
36.24%